KRAS and rectal cancer: High circulating serum miR-345 was found to correlated with unfavorable preoperative chemoradiotherapy response and poor locoregional control in locally advanced rectal cancer [20] and its high expression in blood in metastatic CRC was associated with worse outcome in non-KRAS mutant patients treated with 3rd Line Cetuximab and Irinotecan [53].